HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
(1, 2)
,
(3)
,
(4, 5)
,
(6)
,
(7)
,
(8)
,
(9)
,
(10)
,
(11)
,
(12)
,
(10)
,
(13)
,
(14)
,
(15)
,
(7)
,
(16)
,
(17)
,
(18)
,
(16)
,
(19)
,
(1)
,
(20, 21)
,
(22)
,
(17)
,
(23)
,
(24)
,
(25)
,
(26)
,
(17)
,
(27, 28)
,
(6)
,
(1)
,
(29)
,
(30)
,
(27, 28)
,
(31)
,
(32)
,
(1, 33)
,
(34)
,
(35, 36)
,
(37)
,
(38, 39)
,
(40)
,
(41)
,
(42)
,
(43)
,
(34)
,
(12)
,
(44)
,
(27, 28)
,
(27, 28)
,
(45)
,
(46, 34)
,
(37)
,
(10)
,
(47)
,
,
(46, 34)
,
(48)
,
(49)
,
,
(50)
,
(29)
,
(17)
,
(51)
,
(1)
,
(52)
,
(53)
,
(7)
,
(54)
,
(55)
,
(25)
,
(25)
,
(56)
,
(9)
,
(57)
,
(41)
,
(58)
,
(59)
,
(60)
,
(16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Cristina Belizna
- Function : Correspondent author
Sébastien Abad
- Function : Author
- PersonId : 774635
- IdRef : 184462436
Howard Amital
- Function : Author
- PersonId : 767588
- ORCID : 0000-0002-5406-7716
Laurent Arnaud
- Function : Author
- PersonId : 735667
- IdHAL : laurent-arnaud
- ORCID : 0000-0002-4432-4205
- IdRef : 026691019
Patrick Blanco
- Function : Author
- PersonId : 756121
- ORCID : 0000-0002-5374-3639
Jan Willem Cohen Tervaert
- Function : Author
Céline Fassot
- Function : Author
- PersonId : 182717
- IdHAL : celine-fassot
- ORCID : 0000-0003-0145-8411
- IdRef : 241982189
Milena Hasan
- Function : Author
- PersonId : 749483
- IdHAL : milena-hasan
- ORCID : 0000-0002-0879-7099
Daniel Henrion
- Function : Author
- PersonId : 178861
- IdHAL : daniel-henrion
- ORCID : 0000-0003-1094-0285
- IdRef : 092696252
Estibaliz Lazaro
- Function : Author
- PersonId : 756120
- ORCID : 0000-0002-4206-7399
Laurent Loufrani
- Function : Author
- PersonId : 738906
- IdHAL : laurent-loufrani
- ORCID : 0000-0003-3397-2335
- IdRef : 191329398
Guillaume Mahé
- Function : Author
- PersonId : 963280
Thierry Martin
- Function : Author
- PersonId : 183399
- IdHAL : thierrymartin105
- ORCID : 0000-0001-8320-7055
Christian Muchardt
- Function : Author
- PersonId : 740091
- IdHAL : muchardt
- ORCID : 0000-0003-0145-4023
- IdRef : 111170133
Gyorgy Nagy
- Function : Author
Loukman Omarjee
- Function : Author
Florence Perrinet
- Function : Author
Abstract
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3].Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16].Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency.Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial.This trial consists in two parts: a retrospective and a prospective study.The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.